Brief: Anaptys Announces New Positive Phase 2B Trial Results For Rosnilimab In Rheumatoid Arthritis
29/10/2025 14:35
Oct 29 (Reuters) - AnaptysBio Inc ANAB.O: ANAPTYS ANNOUNCES NEW POSITIVE PHASE 2B TRIAL RESULTS FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT ACR LATE-BREAKING ORAL PRESENTATION ANAPTYSBIO INC - ROSNILIMAB SHOWS EFFICACY IN RA WITH CDAI REMISSION ANAPTYSBIO INC - ROSNILIMAB WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text: ID:nGNXZgw4h Further company coverage: ANAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged